

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 – 15 (Cancelled).

Claim 16 (New): A sustained release injection formulation, comprising

- a. a therapeutic drug or active ingredient ; and
- b. dimethicone as dispersing medium.

Claim 17 (New): The sustained release injection formulation of claim 16, further comprising an adjuvant.

Claim 18 (New): The sustained release injection formulation of claim 17, wherein said adjuvant is a non-ionic surfactant, suspending agent, material for sustained release, antioxidant and local analgesics.

Claim 19 (New): The sustained release injection formulation of claim 16, wherein said therapeutic drug or active ingredient is an avermectin, a NSAID, a parasiticide, an antibiotic, a sex hormone, an oil soluble vitamin or a mineral element which is substantially insoluble in water.

Claim 20 (New): The sustained release injection formulation of claim 19, wherein said avermectin is selected from the group consisting of abamectin, ivermectin, emamectin, eprinomectin, doramectin, moxidectin, and 4"-O- carbamylmethyl- avermectin B1; said NSAID is selected from COX-2 inhibitor, indomethacin, ketoprofen, meloxicam, naproxen, caprofen, ketorolac, flunixin, diclofenac and piroxicam; said parasiticide is selected from the group consisting of imidacloprid, diflubenzuron, lufenuron, methoprene, fipronil, pyriproxyfen, cyromazine, toltrazuril, diclazuril, closantel, closantel sodium, albendazole, and albendazole sulfoxide hydrochloride; said antibiotic is selected from cephalosporin, penicillin,  $\beta$ -lactamase

inhibitor, thiamuline, tiamulin fumarate, tylosins, doxycycline, doxycycline hydrochloride, minocycline, gentamycin, lincomycin, clindamycin, neomycin, polymyxin, quinolones, and sulfanilamide; and said sex hormone is estrogen, progesterone or androgen.

**Claim 21 (New):** The sustained release injection formulation of claim 18, wherein said adjuvant is selected from the group consisting of polyglycerol fatty acid esters, sugar ester, sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters, Myrjs, Brijs, Paregal, OP, polyvinyl chloride hydrogenated castor oil, condensation compound, pluronic, fatty acid esters, hydrogenated castor oil, lanolin, cetanol, stearic acid, poly vinyl pyrrolidone, polyethylene glycol with molecular weight larger than 1000, gelatin, gum Arabic, ethylcellulose and polyvinyl butyral.

**Claim 22 (New):** The sustained release injection formulation of claim 16, comprising

- a. avermectins 0.5-30%, W/V;
- b. hydrogenated castor oil 0-10%, W/V;
- c. local analgesics 0.5-3% W/V;
- d. BHT, BHA,PG, or the combination 0.2%, W/V; and
- e. dimethicone to the final volume

**Claim 23 (New):** The sustained release injection formulation of claim 16, comprising

- a. avermectins 1-10%, W/V;
- b. hydrogenated castor oil 1-5%, W/V;
- c. trichlorobutanol 0.5%, W/V;
- d. BHT/BHA/PG 0.2%, W/V; and
- e. dimethicone with viscosity less than 100mm<sup>2</sup>/S to the final volume.

**Claim 24 (New):** The sustained release injection formulation of claim 16, comprising

- a. carrier particle comprising avermectin 2-35%, W/V;
- b. suspending agent 0-3%, W/V;

- c. local analgesic 0.5-2.5%, W/V;
- d. dimethicone to the final volume;
- e. optionally, antioxidant 0.1~1%

Claim 25 (New): The sustained release injection formulation of claim 24, wherein said carrier particle is in the form of a solid dispersion, microsphere, microcapsule, nanoparticle or liposome.

Claim 26 (New): The sustained release injection formulation of claim 16, wherein said carrier is ethylcellulose, hydrogenated castor oil, PVP, or PEG with MW larger than 1000

Claim 27 (New): The sustained release injection formulation of claim 16, comprising:

- a. NSAIDs 1-15%, W/V;
- b. hydrogenated castor oil 0-5%, W/V;
- c. dimethicone to the final volume; and
- d. optionally, antioxidant or local analgesics.

Claim 28 (New): The sustained release injection formulation of claim 16, comprising:

- a. fipronil, diflubenzuron or imidacloprid 2-10%,W/V;
- b. hydrogenated castor oil 0.2-5%,W/V;
- c. dimethicone to the final volume; and
- d. optionally, antioxidant or local analgesic.

Claim 29 (New): The sustained release injection formulation of claim 16, comprising:

- a. penicillins or cephalosporins 2-40%, W/V;
- b. hydrogenated castor oil 0-5%, W/V;
- c. dimethicone to the final volume; and
- d. antioxidant or local analgesic.